Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (Nasdaq: DMII) is a blank-check company formed to identify and complete a business combination with a target in the domestic pharmaceutical manufacturing and life sciences sector. The vehicle is the second SPAC in this series from the same sponsor group, continuing a strategic focus on reshoring drug production to the United States — a theme that gained regulatory and legislative tailwinds following pandemic-era supply-chain disruptions. DMII filed its most recent Form 10-Q with the SEC on August 14, 2026, indicating the company remains in its search phase. Investors seeking the full deal timeline, warrant structure, and target pipeline can access comprehensive data on SpacDesk — sign up at spacdesk.com for complete coverage.